Under PREA, the U.S. Food and Drug Administration (FDA) requires that drug manufacturers submit a pediatric study plan (PSP) when developing new drugs or biologics. This plan outlines how the company will conduct studies to assess the drug's safety and efficacy in children. The FDA reviews and approves these plans, and the studies must be completed before the drug can be approved for pediatric use.
